.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,327,114

« Back to Dashboard
Patent 9,327,114 protects ZECUITY and is included in one NDA. There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has ten patent family members in ten countries.

Summary for Patent: 9,327,114

Title:User-activated self-contained co-packaged iontophoretic drug delivery system
Abstract: A user-activated self-contained co-packaged iontophoretic drug delivery system and method of use for treatment of a subject are described.
Inventor(s): Sebree; Terri B. (Gladwyne, PA), Stathopulos; Robert P. (Boonton, NJ), Vinatoru; Mihai A. (Graham, NC)
Assignee: Teva Pharmaceuticals International GmbH (Rapperswil-Jona, CH)
Application Number:13/802,156
Patent Claim Types:
see list of patent claims
Compound; Delivery; Use; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Teva Branded Pharm
ZECUITY
sumatriptan succinate
SYSTEM;IONTOPHORESIS202278-001Jan 17, 2013RXYes9,327,114► subscribeY METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,327,114

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2011332187► subscribe
Canada2817824► subscribe
Japan2013543773► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc